FDA clears Talzenna plus Xtandi for earlier, gene-mutated prostate cancer
Pfizer's PARP inhibitor combination is now approved for metastatic, hormone-sensitive prostate cancer with HRR gene mutations. In the 599-patient TALAPRO-3 trial it cut the risk of progression or death by 52%, and Pfizer estimates 77% of patients were progression-free at three years; severe anemia was common (51% vs. 3%).